Rufinamide
- Generic Name
- Rufinamide
- Brand Names
- Banzel, Inovelon
- Drug Type
- Small Molecule
- Chemical Formula
- C10H8F2N4O
- CAS Number
- 106308-44-5
- Unique Ingredient Identifier
- WFW942PR79
- Background
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
- Indication
治疗4岁以上及成人Lennox-Gastaut症候群的癫痫症。
- Associated Conditions
- Lennox-Gastaut Syndrome
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT06740825
- Locations
- 🇺🇸
WCT, San Antonio, Texas, United States
Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- University of South Alabama
- Registration Number
- NCT04558580
- Locations
- 🇺🇸
University of South Alabama, Mobile, Alabama, United States
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
- Conditions
- Lennox Gastaut Syndrome
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT03778424
- Locations
- 🇵🇱
Generała Tadeusza Kościuszki 52, Kielce, Poland
🇵🇱Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland
Population Pharmacokinetics of Antiepileptic in Pediatrics
- Conditions
- Epilepsy
- Interventions
- Biological: brivaracétamBiological: pregabalineOther: genetic polymorphisms
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT03196466
- Locations
- 🇫🇷
AP-HP Cochin, Paris, France
Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 40
- Registration Number
- NCT02332174
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 707
- Registration Number
- NCT02175173
Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- University of Zurich
- Registration Number
- NCT02095899
- Locations
- 🇨🇭
University Hospital Zurich, Institut of Anaesthesiology, Zurich, ZH, Switzerland
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
- Conditions
- Lennox-Gastaut Syndrome
- Interventions
- Drug: Any other approved Antiepileptic Drug
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01405053
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT01151540
A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 66
- Registration Number
- NCT01146951
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.